10x Genomics
TXG Healthcare Medical Devices
10x Genomics' revenue for fiscal 2025 (year ended December 2025) was $642.8 million, up 5.25% from fiscal 2024.
- Revenue
- +1.12%
- EPS
- +31.8%
- Free cash flow
- −4.61%
Quarter to September 2026, against a year earlier
Follow TXG
Alert me
10x Genomics 10-Q filed Nov 6, 2026
Red flags
-
Receivables outpacing revenue
Receivables grew 27.2% while revenue grew 1.1% year over year
What changed
Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 7, 2026: 3 added · 2 removed · 26 modified; 6 with only figures updated
-
Modified · Overview
We are a life sciences technology company focused on building innovative products and solutions to interrogate, understand and master biology. Our integrated research solutions
includeconsist of instruments, consumables and softwarefor analyzing biological systems at resolution and scale that matches the complexity of biology. Our commercial product portfolio is made up ofacross our Single Cell and Spatialsolutionsportfolios. Ourproducts include ourinstruments, whichinclude our Chromium instruments, our Visium CytAssistfor Single Cell and our Visium CytAssist, Xenium Analyzer,andour consumables, whichAtera instruments for Spatial. Our consumables include proprietary microfluidic chips, slides, reagents and other consumablesforused with ourSingle CellChromium, Visium, Xenium andSpatialAtera solutions. We bundle our software with these products toguidesupport customersthrough the workflow’ experiments, from sample preparation through data analysis and visualization. Customers purchase instruments and consumables from us for use in their experiments. We also derive revenue from post-warranty service contracts for our instruments.